ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
94,819.01
0.45%
S&P 500
5,881.63
-0.43%
Dow Jones
42,544.22
-0.07%
US Dollar vs Yen
157.186
-0.35%
Brent Oil
74.915
1.44%
Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Coeptis Therapeutics Holdings Inc (COEP)

  7. Coeptis Therapeutics Holdings Inc (COEP) ニュース

COEP

Coeptis Therapeutics (COEP)

Coeptis Therapeutics Holdings Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:COEP
日付受信時刻ニュースソース見出しコード企業名
2025/01/0104 : 20AllPennyStocks.comTrading Halt Occurred During This Micro Cap's EOY SurgeNASDAQ:COEPCoeptis Therapeutics Holdings Inc
2024/12/2722 : 15PR Newswire (US)Coeptis Therapeutics Announces Reverse Stock SplitNASDAQ:COEPCoeptis Therapeutics Holdings Inc
2024/12/2622 : 15PR Newswire (US)Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis TechnologiesNASDAQ:COEPCoeptis Therapeutics Holdings Inc
2024/12/1222 : 00PR Newswire (US)Coeptis Therapeutics Unveils New Technology Division: Coeptis TechnologiesNASDAQ:COEPCoeptis Therapeutics Holdings Inc
2024/12/0322 : 15PR Newswire (US)Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other IndustriesNASDAQ:COEPCoeptis Therapeutics Holdings Inc
2024/11/0722 : 07PR Newswire (US)Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical DevelopmentNASDAQ:COEPCoeptis Therapeutics Holdings Inc
2024/10/2421 : 07PR Newswire (US)Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency UseNASDAQ:COEPCoeptis Therapeutics Holdings Inc
2024/10/1521 : 07PR Newswire (US)Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell TherapyNASDAQ:COEPCoeptis Therapeutics Holdings Inc
2024/09/1920 : 07PR Newswire (US)Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
2024/09/0521 : 07PR Newswire (US)Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to ShareholdersNASDAQ:COEPCoeptis Therapeutics Holdings Inc
2024/08/1705 : 02Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:COEPCoeptis Therapeutics Holdings Inc
2024/08/1705 : 01Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:COEPCoeptis Therapeutics Holdings Inc
2024/08/1506 : 26Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:COEPCoeptis Therapeutics Holdings Inc
2024/08/1506 : 25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COEPCoeptis Therapeutics Holdings Inc
2024/08/0106 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COEPCoeptis Therapeutics Holdings Inc
2024/06/2021 : 47PR Newswire (US)Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred OfferingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
2024/05/3021 : 47PR Newswire (US)Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual MeetingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
2024/05/0821 : 47PR Newswire (US)Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024NASDAQ:COEPCoeptis Therapeutics Holdings Inc
2024/05/0221 : 47PR Newswire (US)Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual MeetingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
2024/04/0221 : 47PR Newswire (US)Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research AwardNASDAQ:COEPCoeptis Therapeutics Holdings Inc
2024/02/2623 : 00PR Newswire (US)Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NKNASDAQ:COEPCoeptis Therapeutics Holdings Inc
2024/02/0721 : 30PR Newswire (US)Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral InfectionsNASDAQ:COEPCoeptis Therapeutics Holdings Inc
2024/01/0421 : 30PR Newswire (US)Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024NASDAQ:COEPCoeptis Therapeutics Holdings Inc
2023/10/3122 : 01PR Newswire (US)Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023NASDAQ:COEPCoeptis Therapeutics Holdings Inc
2023/10/2421 : 30PR Newswire (US)Coeptis Therapeutics Announces $2 Million Private PlacementNASDAQ:COEPCoeptis Therapeutics Holdings Inc
2023/10/1120 : 30PR Newswire (US)Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell TechnologyNASDAQ:COEPCoeptis Therapeutics Holdings Inc
2023/10/0922 : 15PR Newswire (US)Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene TherapiesNASDAQ:COEPCoeptis Therapeutics Holdings Inc
2023/10/0420 : 30PR Newswire (US)Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual MeetingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
2023/09/2720 : 30PR Newswire (US)Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the MesaNASDAQ:COEPCoeptis Therapeutics Holdings Inc
2023/09/1420 : 30PR Newswire (US)Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 InfectionNASDAQ:COEPCoeptis Therapeutics Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:COEP

最近閲覧した銘柄

AMEX
XLE
Energy Select Sector SPDR
NYSE
JPM
JP Morgan Chase
NASDAQ
NVDA
NVIDIA
NYSE
NKE
Nike
NYSE
BAC
Bank of America
COIN
ETHUSD
Ethereum
NASDAQ
GOOGL
Alphabet
FX
USDEUR
US Dollar vs Euro
CCOM
US500
US 500
COIN
XRPUSD
Ripple
NASDAQ
MSFT
Microsoft
NYSE
XOM
Exxon Mobil
USI
USTECH100
US Tech 100
USOTC
BNPQY
BNP Paribas (QX)
COIN
ADAUSD
Cardano
NYSE
MRK
Merck
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有